|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
|
31076742 |
2020 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Comprehensive Profiling of BRCA1 and BRCA2 Variants in Breast and Ovarian Cancer in Chinese Patients.
|
31825140 |
2020 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In the present study, 21 BRCA1 and BRCA2 pathogenic variants were detected in 30 patients and BRCA1/2 mutations were significantly associated with a family history of breast/ovarian cancer.
|
31706072 |
2020 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Germline mutations (eg, BRCA1/2) have prognostic and treatment implications for ovarian cancer (OVCA) patients.
|
31600840 |
2020 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Analyses performed under logistic model, linear mixed model, and model incorporating correlations identified nine significant associations with three gynecologic diseases including four novel findings (rs79219469:C > T, LINC02183, P = 3.3 × 10<sup>-8</sup> and rs567534295:C > T, BRCA1, P = 3.1 × 10<sup>-8</sup> with OC, rs150806792:C > T, INS-IGF2, P = 4.9 × 10<sup>-8</sup> and rs140991990:A > G, SOX9, P = 3.3 × 10<sup>-8</sup> with UCC).
|
31488892 |
2020 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A simultaneous detection of germline and somatic mutations in ovarian cancer (OC) using tumor materials is considered to be cost-effective for <i>BRCA1/2</i> testing.
|
31788999 |
2020 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
|
31699415 |
2020 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
BRCA1-driven OCs demonstrate the plasticity of BRCA1 status during the treatment course.
|
31693165 |
2020 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.
|
31719105 |
2020 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In adjusted analysis, age ≥80 years (odds ratio [OR] 0.10; P = 0.002), psychiatric disorders (OR 0.46; P = 0.006), occupation requiring at least 3 years of university or college education (OR 2.03; P = 0.003), and breast cancer or ovarian cancer in first-degree or second-degree relatives (OR 1.66; P = 0.02) were independently associated with uptake of BRCA1/2 testing.
|
29875420 |
2019 |
|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Patients with BC and OC and brain metastases have a frequent loss of BRCA1 expression.
|
30822630 |
2019 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRCA1/2 mutations were significantly associated with family history of breast/ovarian cancer (p<0.001), serous histology (p=0.044), and advanced International Federation of Gynecology and Obstetrics (FIGO) stage (III/IV, p=0.018) but not with early age-of-onset (age < 50, p=0.729).
|
30309222 |
2019 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.
|
31500890 |
2019 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Surveillance of patients with mutations in BRCA 1/2 is done by yearly mammography and breast MRI and by transvaginal ultrasonography and serum CA-125 levels every 6-12 months for ovarian cancer.
|
30358186 |
2019 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Worry about ovarian cancer risk predicted use of preventative pBSO among high-risk women including those with BRCA1/2 mutations enrolled in an ovarian cancer-screening program.
|
30431292 |
2019 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The study includes 1246 individuals assessed for BRCA1/2 genetic testing in Navarra, during 2000-2016, and a cohort of BC (n = 4384) and OC (n = 561) from the population-based Navarra Cancer Registry.
|
31771539 |
2019 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations occurring in the highly penetrant genes BRCA1 and BRCA2 are responsible for only certain cases of familial breast cancer (BC) and ovarian cancer (OC).
|
30733081 |
2019 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The combined analyses revealed that deleterious germline variants in established OC predisposition genes (all: 125/473, 26.4%; <i>BRCA1/2</i>: 97/473, 20.5%), deleterious somatic variants in established OC predisposition genes excluding <i>TP53</i> (all: 39/473, 8.2%; <i>BRCA1/2</i>: 30/473, 6.3%) and promoter methylation (all: 67/473, 14.2%; <i>BRCA1</i>: 57/473, 12.1%; <i>RAD51C</i>: 10/473, 2.1%; <i>PALB2</i>: 0/473) were mutually exclusive, with a few exceptions.
|
30979843 |
2019 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Women with a BRCA1 or BRCA2 mutation face high risks of breast and ovarian cancer.
|
30971774 |
2019 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Deleterious mutations in BRCA1 or BRCA2 genes increase a woman's lifetime risk of breast and ovarian cancer.
|
29863445 |
2019 |
|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
This study was designed to determine the frequency of three single nucleotide polymorphisms (SNPs) variants in BRCA1 gene and BRCA1 expression in Saudi females with ovarian cancer.
|
30820179 |
2019 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling.
|
30334464 |
2019 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Significant associations with OC were observed in <i>BRCA1, BRCA2, RAD51C</i> and <i>RAD51D.</i> Other homologous recombination genes, <i>BARD1, NBN,</i> and <i>PALB2,</i> were not significantly associated with OC.
|
31341520 |
2019 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The SOLO1 trial randomized women with <i>BRCA1/2</i>-mutated advanced ovarian cancer to olaparib or placebo maintenance after first-line chemotherapy.
|
31037967 |
2019 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inherited mutations in the breast cancer susceptibility genes <i>BRCA1</i> and <i>BRCA2</i> (<i>BRCA1/2</i>) confer high risks of breast and ovarian cancer.
|
30541753 |
2019 |